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Eicosapentaenoic acid and docosahexaenoic
acid reduce interleukin-1b-mediated cartilage
degradation
Angus KT Wann1, Jiten Mistry1, Emma J Blain3, Adina T Michael-Titus2, Martin M Knight1*
Abstract
Introduction: In inflammatory joint disease, such as osteoarthritis (OA), there is an increased level of
proinflammatory cytokines, such as interleukin (IL)-1b. These cytokines stimulate the production of matrix
metalloproteinases (MMPs), which leads to the degradation of the cartilage extracellular matrix and the loss of key
structural components such as sulphated glycosaminoglycan (sGAG) and collagen II. The aim of this study was to
examine the therapeutic potential of n-3 polyunsaturated fatty acids (PUFAs) in an in vitro model of cartilage
inflammation.
Methods: Two specific n-3 compounds were tested, namely, eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA), each at 0.1, 1 and 10 μM. Full thickness bovine cartilage explants, 5 mm in diameter, were cultured for
5 days with or without IL-1b and in the presence or absence of each n-3 compound. The media were replaced
every 24 hours and assayed for sGAG content using the 1,9-dimethylmethylene blue (DMB) method. Chondrocyte
viability was determined at the end of the culture period using fluorescence microscopy to visualise cells labelled
with calcein AM and ethidium homodimer.
Results: Treatment with IL-1b (10 ng.ml-1) produced a large increase in sGAG release compared to untreated
controls, but with no effect on cell viability, which was maintained above 80% for all treatments. In the absence of
IL-1b, both n-3 compounds induced a mild catabolic response with increased loss of sGAG, particularly at 10 μM.
By contrast, in the presence of IL-1b, both EPA and DHA at 0.1 and 1 μM significantly reduced IL-1b-mediated
sGAG loss. The efficacy of the EPA treatment was maintained at approximately 75% throughout the 5-day period.
However, at the same concentrations, the efficacy of DHA, although initially greater, reduced to approximately half
that of EPA after 5 days. For both EPA and DHA, the highest dose of 10 μM was less effective.
Conclusions: The results support the hypothesis that n-3 compounds are anti-inflammatory through competitive
inhibition of the arachidonic acid oxidation pathway. The efficacy of these compounds is likely to be even greater
at more physiological levels of IL-1b. Thus we suggest that n-3 PUFAs, particularly EPA, have exciting therapeutic
potential for preventing cartilage degradation associated with chronic inflammatory joint disease.
Introduction
Articular cartilage allows relatively frictionless motion of
the diarthrodial joint and serves as a unique load-bearing
material. The properties of the tissue are related to the
composition and structure of the extracellular matrix,
which is maintained by the chondrocytes. This hydrated
matrix consists of proteoglycan aggregates, containing
sulphated glycosaminoglycans (sGAG), which are
entangled in a meshwork of collagen, predominantly type
II. Chondrocytes synthesise the various matrix compo-
nents as well as enzymes which lead to their catabolism
(aggrecanases and matrix metalloproteinases, or MMPs)
and inhibitors of these enzymes, namely, tissue inhibitors
of metalloproteinases (TIMPs). In healthy tissues, a
balance is maintained between matrix synthesis and
degradation.
Osteoarthritis (OA) is characterised by the progressive
breakdown of the cartilage extracellular matrix. Increased
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aggrecan cleavage by aggrecanases leads to the loss of
entrapped sulphated GAG and surrounding type II col-
lagen, leading ultimately to joint cartilage destruction
and the exposure of underlying bone [1-4].
Inflammatory cytokines, including interleukin (IL)-1b,
have been detected in the synovial fluid of OA patients
in the 1-4 pg/ml range [5]. It is well established that
IL-1b stimulates cartilage breakdown [6,7]. Conse-
quently numerous in vitro studies have used this cyto-
kine in models of inflammatory OA [8-12]. Such studies
have highlighted the procatabolic effects of IL-1 by mea-
suring the expression of inflammatory markers such as
MMP levels and cyclooxygenase (COX) and the release
of matrix degradative products [13,14]. An understand-
ing of inflammatory progression in the tissue, especially
matrix degradation, exists, but the development of suc-
cessful therapeutic interventions to halt this destructive
process is in its infancy.
Certain polyunsaturated fatty acids (PUFAs) including
eicosapentaenoic acid (EPA) and arachidonic acid (AA),
n-3 and n-6 fatty acids, respectively, are “essential” to
the health of mammals. Indeed, dietary PUFAs of both
the n-3 and n-6 series have long been heavily implicated
in human health [15]. Long chain n-3 fatty acids are
present in fish and marine mammals, and epidemiologi-
cal data indicate a correlation between fish-wealthy diets
and reduced incidence of inflammatory disease [16]. It
has been postulated that humankind evolved on a diet
with a ratio of n-6:n-3 fatty acids of approximately 1:1,
whereas, at least in Western society, the prevailing ratio
in modern times is 10-20:1 [17]. In a variety of condi-
tions, including neurological damage [18], cardiovascular
disease [19] and rheumatoid arthritis [20] n-3 com-
pounds have been shown to offer therapeutic benefit.
Recent animal studies have also reported that n-3 fatty
acids may have therapeutic benefit in OA [21]. This
may be associated with increased collagen synthesis and
decreased amounts of the inflammatory mediator pros-
taglandin E2 as reported in fibroblasts in vitro [22].
In general, the two series of fatty acids are thought to
have opposing effects in the context of inflammation.
Oxidation of n-6 fatty acids by the COX enzyme system
gives rise to proinflammatory “2” series eicosanoids,
such as the prostaglandin PGE2, and “4” series leuko-
trienes such as LTB4. By contrast, oxidation of n-3 series
members give rise to the lesser inflammatory molecules
of PGE3, following COX oxidation, and LTB5, following
lipooxygenase activity [23]. The resultant competitive
inhibition of AA oxidation represents the primary the-
ory by which n-3 fatty acids may elicit therapeutic anti-
inflammatory effects [23].
Here we test the hypothesis that the long-chain n-3
fatty acids, eicosapentaenoic acid (EPA) and docosahex-
aenoic acid (DHA), reduce cytokine-induced articular
cartilage degradation as characterised by the release of
sGAG from the tissue.
Materials and methods
Reagents and media preparation
Dulbecco’s modified Eagle’s medium (DMEM) was sup-
plemented with 1.6 mM L-glutamine, 81 U/ml penicillin,
80 μg/ml streptomycin, 16 mM 2-[4-(2-hydroxyethyl)
piperazin-1-yl]ethanesulfonic acid (or HEPES) buffer, and
0.68 mM ascorbic acid. This medium was used either on
its own or with the addition of 16% (vol/vol) foetal calf
serum (FCS). All of the above reagents were from Sigma-
Aldrich (Poole, UK). IL-1b was obtained from Peprotech
(London, UK) and was reconstituted to 1 mg.mL-1 from
solid lyophilised sterile powder in distilled water follow-
ing centrifugation. This stock was then added to serum-
free supplemented DMEM and frozen down in aliquots
at 10 μg.mL-1. When required, aliquots of IL-1b were
thawed and diluted to 10 ng.ml-1 in serum-free medium
containing bovine serum albumin (BSA; Sigma-Aldrich)
at a final concentration of 0.1%. The fatty acids, cis-
5,8,11,14,17-eicosapentaenoic acid (EPA) and cis-
4,7,10,13,16,19-docosahexaenoic acid (DHA) were also
obtained from Sigma-Aldrich and prepared into 1 M
solutions in ethanol. These stock solutions were mixed
1:1 with 30% fatty acid free BSA (Sigma-Aldrich, Poole,
UK) in phosphate-buffered saline (PBS) and diluted with
serum-free medium to obtain aliquots at 100 μM which
were frozen. Aliquots were freshly defrosted on the day
of use and diluted in serum-free medium to concentra-
tions of 0.1, 1 and 10 μM for both EPA and DHA. Fatty
acid concentrations that were an order of magnitude
above those used in this study are readily achievable in
the plasma compartment following nutritional supple-
mentation [24]. Here the stock solutions and resultant
medium were not filtered after addition of the com-
pounds to ensure dose accuracy. Vehicle concentrations
tested were therefore 0.1% albumin and 0.0789, 0.789
and 7.89 μM ethanol.
1,9-dimethylmethylene blue (DMB) powder (Sigma-
Aldrich) was reconstituted in ethanol and then in a 29
mM sodium formate/distilled water solution and finally
the pH was adjusted to 3. DMB was used at a final
concentration of 16 μg.mL-1. Chondroitin sulphate
(6-sulphate:4-sulphate; 0.33:1) standards (Sigma-Aldrich)
were made up at 0-50 μg.mL-1 in the appropriate treat-
ment medium for the sample being assayed.
Tissue explant isolation and culture
Eight to ten bovine forefeet from 18-month-old steers
were obtained fresh from slaughter from a local abattoir.
Full-depth tissue explants were taken from the proximal
surface of the metacarpalphalangeal joint under sterile
conditions. The circular explants, 5 mm in diameter,
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were cut out by slowly rotating a dermal punch (Miltex,
York, PA, USA) down through to the subchondral bone
and removing them with a scalpel blade (Figure 1a).
Explants were immediately placed into DMEM plus FCS
and incubated at 37°C in 5% CO2. After 24 hours,
explants were weighed and placed in 2 ml of fresh
DMEM plus FCS in separate wells for 72 hours (Figure
1b). At 96 hours, the explants were thoroughly washed
(3 × 5 min) to remove any serum. Groups of explants
(n = 10) were then cultured for 120 hours in serum-free
medium in the presence or absence of IL-1b (10 ng.mL-1)
and supplemented with or without either EPA or DHA.
The EPA and DHA were used at three different concen-
trations, namely, 0.1, 1 and 10 μM. An untreated control
group was cultured in serum-free medium. Medium was
removed every 24 hours for subsequent biochemical ana-
lysis and replaced with the appropriate fresh medium.
Separate studies were conducted to examine the influ-
ence of the two vehicles for IL-1b and the fatty acids,
namely, BSA and ethanol. The final concentrations of
each vehicle are given in Table 1.
For simplicity, any effect of the BSA used in the pre-
paration of the n-3 compounds, EPA or DHA, was
assumed to be negligible compared to the much greater
concentration used for IL-1b (0.1%). Thus vehicle stu-
dies examined the effects of BSA at 0.1% and ethanol at
0.0789, 0.789 and 7.89 μM.
Tissue viability
At the end of the culture period, one explant from each
group was used to assess cell viability. The explant was
incubated in a solution of 5 μM calcein AM and 5 μM
ethidium homodimer (Invitrogen, Paisley, UK) for 60
minutes at 37°C. Full-depth sections 1 mm in thickness
were cut using a scalpel, mounted on a fluorescence
microscope and visualised with a × 20 objective. Live
and dead cells are labelled green and red by calcein AM
and ethidium homodimer, respectively. Percentage cell
viability was calculated from at least 10 fields of view.
Figure 1 Chondrocyte viability is maintained in cartilage explants taken from the bovine metacarpal phalangeal joint. Full-depth
cartilage explants were removed from the proximal surface of bovine metacarpal phalangeal joints (a) and cultured in 24-well plates with 2 ml
of culture medium/explant/well (b). Cell viability was assessed at the end of the culture period using fluorescence microscopy. Full-depth slices
were removed from the explant and incubated in calcein AM, which labels live cells green, and ethidium homodimer, which labels dead cells
red (c).
Table 1 Final concentrations of vehicles in the eight
treatment groupsa
Bovine serum albumin
(%)
Ethanol
(μM)
IL-1 only 0.1 0
IL-1 + 0.1 μM n-3
compound
0.100003 0.0789
IL-1 + 1 μm n-3 compound 0.10003 0.789
IL-1 + 10 μm n-3
compound
0.1003 7.89
0.1 μM n-3 compound 0.000003 0.0789
1 μm n-3 compound 0.00003 0.789
10 μm n-3 compound 0.0003 7.89
Untreated control 0 0
aIL-1, interleukin 1.
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Sulphated glycosaminoglycan (sGAG) quantification
The quantity of sGAG release into media was quantified
in triplicate using the 1,9-dimethylmethylene blue
(DMB) assay [25] with chondroitin sulphate calibration
standards made up in media representing the treatment
group being assayed. Samples were double- or triple-
diluted, as necessary, to bring them into the range of
the standards. Absorbance was read at 595 nm. The
sGAG content was normalised to explant wet weight
(approximately 20-30 mg).
As many data sets failed Kolmogorov-Smirnov nor-
mality testing, nonparametric statistical tests were used
in the form of the Mann-Whitney U test and the
Kruskal-Wallis test. Data are presented as median values
with interquartile ranges for samples of 10 explants. All
data and statistical analyses were conducted using
GraphPad Prism 5 software (GraphPad Software, La
Jolla, CA, USA).
Results
Cell viability
Mean cell viability for each treatment group is presented
in Table 2, based on images of cells stained with calcein
AM and ethidium homodimer at the end of the culture
period. None of the treatment protocols had a statisti-
cally significant effect on cell viability (P > 0.05; one-way
analysis of variance, or ANOVA). In all cases, viability
was maintained above 80%. The majority of cell death
was observed in all groups at the explant surfaces.
Effect of IL-1b on sGAG release
Over the entire untreated culture period, sGAG was
released from the cartilage explants into the culture
media. Treatment with 10 ng.mL-1 IL-1b produced a
large increase in sGAG release, which was maintained
over the 120-hour treatment period. Thus the cumula-
tive sGAG released into the culture media was substan-
tially greater than that for untreated controls at all time
points (Figure 2), with all the differences being statisti-
cally significant (P < 0.001; Mann-Whitney U tests, n =
20). By the end of the culture period, after 120 hours of
treatment, the IL-1b-treated explants showed a 38-fold
increase in the amount of sGAG released compared
with untreated controls. Although the absolute quantity
of sGAG released per 24 hours increased over the
120-hour treatment period, the levels relative to
untreated controls were greatest in the initial 24-hour
period, decreasing thereafter (Figure 3).
Influence of vehicles, BSA and ethanol
The vehicles used for IL-1b (0.1% BSA) and for EPA
and DHA (ethanol) were also independently tested to
evaluate their contributions. Figure 3 shows the amount
of sGAG released into the medium per 24 hours over
the 120-hour treatment period. Values have been nor-
malised to untreated control values and are plotted
alongside those for IL-1b-treated explants for compari-
son. Kruskal-Wallis tests revealed no consistent statisti-
cally significant differences between the three different
ethanol concentrations (0.0789, 0.789 and 7.89 μM).
The P values at time points 24, 48, 72, 96 and 120
hours were 0.42, 0.06, 0.02, 0.10 and 0.03, respectively.
Hence these data for the separate ethanol concentra-
tions have been pooled. Both vehicles, BSA and ethanol,
produced increased sGAG release into the culture med-
ium compared with untreated controls. The differences
were statistically significant throughout the 120-hour
treatment period, with the exception of ethanol over the
96- to 120-hour period.
The effect of EPA and DHA on sGAG release rate from
cartilage explants
The effects of EPA and DHA on sGAG release rate in the
presence and absence of IL-1b are shown in Figures 4
and 5. The data show the sGAG released into the culture
media per 24 hours, normalised to the initial wet weight
of the explant. In the absence of IL-1b, treatment with
EPA produced a slight increase in mean sGAG release
compared with untreated controls (Figure 4a). The high-
est concentration of EPA, namely 10 μM, produced the
greatest loss of sGAG, with statistically significant differ-
ences at all time points up to 96 hours. In the presence
of IL-1b, rates of sGAG release were attenuated when
explants were treated with 0.1 or 1 μM EPA (Figure 4b).
The differences were statistically significant throughout
the 120-hour treatment period. EPA at 10 μM, however,
failed to attenuate the IL-1b effect at any time point
except 120 hours. Even at 0.1 and 1 μM, EPA failed to
reduce sGAG loss to the level found for control explants
Table 2 Cell viability measured at the end of the entire
culture period for different treatmentsa
Treatment % Cell viability (means ± standard
deviation)
without IL-1b With IL-1b
Control 87 ± 11 89 ± 9
EPA 0.1 μM 90 ± 8 83 ± 10
1.0 μM 91 ± 7 87 ± 7
10 μM 83 ± 10 89 ± 8
DHA 0.1 μM 85 ± 8 86 ± 5
1.0 μM 85 ± 9 88 ± 5
10 μM 83 ± 9 87 ± 10
0.1% BSA (vehicle) 86 ± 5
7.89 μM ethanol
(vehicle)
89 ± 8
aValues represent sample means ± standard deviations for n = 1 explants with
at least 10 fields of view for each explant. EPA, eicosapentaenoic acid; DHA,
docosahexaenoic acid; IL-1b, interleukin 1b; BSA, bovine serum albumin.
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not treated with IL-1b such that the difference remained
statistically significant.
Very similar trends were seen in identical experiments
using DHA. A 10 μM DHA dose induced a small but
statistically significant increase in sGAG release rate
with respect to untreated controls at all time points
(Figure 5a). The lower doses only had a statistically sig-
nificant effect in the early stages of the treatment period.
In the presence of IL-1b, DHA at 0.1 and 1 μM reduced
sGAG loss. The differences between IL-1b-treated
explants and those supplemented with DHA at 0.1 and
1 μM were statistically significant for up to 96 hours of
treatment (Figure 5b). Indeed, in the first 24 hours, the
effect was so great that there was no statistically signifi-
cant difference (P > 0.05; Mann-Whitney U test)
between untreated control explants and IL-1b-treated
explants supplemented with 0.1 μM DHA. However,
after 120 hours of treatment, DHA no longer had any
effect on sGAG release in the presence of IL-1b such
that there were no statistically significant differences
between IL-1b-treated explants with and without DHA
(P > 0.05; Mann-Whitney U test).
True corrected efficacy of the n-3 fatty acids and efficacy
with time
The efficacy of the fatty acid treatments was calculated
at each time point using data that were first adjusted for
the influence of the two vehicles, BSA and ethanol
(Equation 1 below). Parameters indicate the mean fold
increase over untreated control. Efficacy (%) =
IL BSA fattyacidtreatment BSA ethanol−( ) − ( )⎡⎣ ⎤⎦ − ( ) − ( ) − ( )⎡⎣ ⎤⎦1
IL BSA−( ) − ( )⎡⎣ ⎤⎦ −
⎧
⎨⎪
⎩⎪
⎫
⎬⎪
⎭⎪
×
1 1
100
An efficacy of 100% indicates that the fatty acid
reduces sGAG loss to that seen in untreated controls.
Figures 6a and 6b show the efficacy for EPA and DHA
treatments, respectively, to view the efficiency trends
with time. The data indicate that EPA at 0.1 and 1 μM
maintains potent efficacy at approximately 75% through-
out the 5-day treatment period. DHA efficacy was initi-
ally very high in the first 24 hours, reducing sGAG loss
below that for untreated control, hence having an effi-
cacy greater than 100%. However, efficacy was reduced
substantially over 5 days for all three concentrations
tested.
To examine the temporal changes in efficacy, a linear
regression was fitted to the data for each treatment and
a Pearson’s correlation analysis was performed. The
results, shown in Table 3, confirm that for all DHA
treatments, there were statistically significant reductions
in efficacy over the 5 days. By contrast, EPA treatment
at 0.1 and 1 μM showed no statistically significant tem-
poral changes in efficacy. At 10 μM, EPA showed a sta-
tistically significant positive correlation with an increase
in efficacy from very low values in the first 72 hours of
treatment to approximately 50% at 120 hours.
Discussion
This work investigated the potential therapeutic anticata-
bolic effects of EPA and DHA by directly measuring tis-
sue degradation in a physiologically relevant, accelerated
Figure 2 Interleukin (IL)-1b produces cartilage degradation
characterised by the release of sulphated glycosaminoglycan
(sGAG). Temporal increase in cumulative sGAG release for untreated
control explants and those cultured in the presence of 10 ng.ml-1
interleukin. Values represent the median cumulative sGAG released
from explants during the treatment period of 120 hours. Error bars
indicate interquartile ranges. The sGAG release from IL-1-treated
explants was statistically greater than that from untreated control
explants at all time points (P < 0.001, n = 20; Mann-Whitney U test).
Figure 3 The vehicles bovine serum albumin (BSA) and ethanol
have a small catabolic effect. Temporal changes in the release of
sGAG for cartilage explants treated with either BSA or ethanol. Data
are normalised to that for untreated control explants and presented
as a fold increase with median values and error bars showing
interquartile ranges. Data are grouped together for all ethanol doses
(0.08-8 μM) as no statistically significant dose-response relationship
was found. Statistically significant differences from untreated
controls are indicated on the basis of Mann-Whitney U tests
(*P < 0.05, **P < 0.01, ***P < 0.001).
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model of inflammatory joint disease. IL-1b treatment at
10 ng.ml-1 as used in previous studies [13,26-28]) power-
fully stimulated the release of sGAG over a 5-day period
in accordance with an acute catabolic response [29]. By
the end of the IL-1b treatment period, explants had
released to the media approximately 15 μg.mg-1 of
sGAG, equivalent to 1-2% of total wet weight and an esti-
mated 15-30% of total proteoglycan. When these data are
normalised to untreated control values, it is clear that
IL-1b-induced sGAG loss was greatest in the first 24
hours and decreased thereafter (Figure 3). Previous stu-
dies have reported that BSA induces cytokine secretion
[30]. Indeed, in the present study, approximately 20-30%
of the procatabolic effects of the IL-1b treatment can
be attributed to the BSA, used here as a vehicle for
the IL-1b.
Studies using chondrocytes in monolayer showed that a
24-hour predose of the n-3 compounds, EPA and DHA,
reduced subsequent mRNA levels for degradative
enzymes relative to IL-1b-stimulated levels [13]. How-
ever, using the explant model and measurement of sGAG
release, preliminary studies found that pretreatment with
EPA or DHA did not alleviate the subsequent catabolic
effects of IL-1b (data not shown).
However, using the prolonged treatment protocol,
EPA and DHA, at 0.1 and 1 μM, did provide a statisti-
cally significant attenuation of IL-1b-mediated tissue
breakdown (Figures 4b and 5b). This occurred despite
EPA and DHA inducing mild catabolic effects of their
own in the absence of IL-1b, particularly at the higher
dose of 10 μm (Figures 4a and 5a). These results sup-
port the hypothesis that oxidisation of these n-3 com-
pounds gives rise to the mildly inflammatory PGE3 and
LTB5, which, in the presence of IL-1b, competitively
inhibit the arachidonic acid pathway [23]. It has addi-
tionally been postulated that EPA blocks the terminal
stages of aracidonic acid synthesis from its precursors
in vivo [31].
Mechanisms have also been proposed which implicate
cell types beyond chondrocytes. One such example sug-
gests that EPA-derived 15-lipoxygenase products inter-
fere with nuclear factor (NF)-B activation, preventing
proinflammatory leukocyte adhesion receptor expres-
sion, and subsequent leukocyte-endothelial interactions
[32]. In addition to this, studies, initially in the context
Figure 4 Treatment with eicosapentaenoic acid (EPA) reduced
the rate of cartilage degradation in the presence of IL-1b. Over
the 120 treatment period, sGAG release was measured in cartilage
explants treated with EPA in the presence (a) and absence (b) of
IL-1b. EPA was used at 0.1, 1 and 10 μM. Median data are shown
with interquartile range error bars. Both sub-figures are on the same
scale for comparative purposes. Statistically significant differences
are shown relative to the untreated control group (a) and the IL-1b
treatment group (b). Analysis was conducted using Mann-Whitney U
tests (*P < 0.05, **P < 0.01, ***P < 0.001).
Figure 5 Treatment with docosahexaenoic acid (DHA) reduced
the rate of cartilage degradation in the presence of IL-1b. Over
the 120 treatment period, sGAG release was measured in cartilage
explants treated with DHA in the presence (a) and absence (b) of
IL-1b. DHA was used at 0.1, 1 and 10 μM. Median data are shown
with interquartile range error bars. Statistically significant differences
are shown relative to the untreated control group (a) and the IL-1b
treatment group (b). Analysis was conducted using Mann-Whitney U
tests (*P < 0.05, **P < 0.01, ***P < 0.001).
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of aspirin, have implicated a new potent anti-inflamma-
tory EPA-derived mediator in the shape of the resolvin
E1 and novel wider anti-inflammatory circuits [33,34].
Our in vitro model isolates the cartilage from systemic
or other local surrounding influence so that the antica-
tabolic effects of EPA and DHA can only be attributable
to competitive inhibition of arachidonic acid oxidation
or other mechanisms mediated solely by chondrocytes.
The therapeutic effects of these n-3 compounds may
therefore be even more profound and longer lasting
in vivo, where broader anti-inflammatory circuits can be
engaged.
The compounds were highly effective in the early peri-
ods, during which the most acute IL-1b effects were seen.
In the case of 0.1 and 1 μM EPA, efficacy was maintained
at approximately 75% throughout the treatment period
(Figure 6a). By contrast, DHA efficacy was initially
greater than that for EPA but significantly reduced with
time (Figure 6b). The reason for this declining efficacy is
as yet unclear. To further elucidate any sustained mode
of action for EPA and DHA, preliminary studies were
conducted to examine the expression of catabolic inflam-
matory genes at the end of the 5-day treatment period.
Using well-established quantitative polymerase chain
reaction (qPCR) techniques previously described [35],
gene expression for ADAMTS 4 and 5; MMPs 3, 9 and
13; and cyclooxygenase 2 (COX2) was assessed relative to
untreated controls and normalised to 18S. IL-1b robustly
raised all six genes consistent with its well-established
mode of action (Table 4). Treatment with EPA reduced
the IL-1b-mediated elevation of these catabolic genes
with the exception of MMP9, which was unaffected. By
contrast, for DHA at the 5-day time point, no such
attenuations were observed. These data concur with the
observed loss of efficacy displayed by DHA in the tissue
degradation studies (Figure 6) and suggest that EPA at
least produces its anticatabolic effect by downregulating
catabolic gene expression.
Conclusions
In conclusion, previous studies using isolated chondro-
cytes have demonstrated that EPA and DHA reduce
catabolic gene expression profiles [13], but this is the
first study to robustly show in a cartilage explant model
that these anticatabolic effects of PUFAs are translated
into reductions in tissue degradation. The n-3 com-
pounds, particularly EPA, which maintains its efficacy,
have exciting therapeutic potential for the treatment of
inflammatory joint diseases such as osteoarthritis.
Figure 6 EPA exhibits are more prolonged anti-catabolic
efficacy compared to DHA. Efficacy of EPA (a) and DHA (b) in
terms of their ability to reduce sGAG loss from cartilage explants
treated with 10 ng.mL-1 IL-1b. See Results for calculation of
percentage efficacy.
Table 3 Linear regression analysis of efficacy with time
calculated using Pearson’s correlationa
Concentration (μM) EPA DHA
0.1 ns P < 0.05 ↓
1 ns P < 0.01 ↓
10 P < 0.05 ↑ P < 0.05 ↓
aData are also presented Figure 6. EPA, eicosapentaenoic acid; DHA,
docosahexaenoic acid. ns, not significantly different. Direction of arrow refers
to positive or negative correlation between efficacy and time.
Table 4 Analysis of gene expression at the end of the
5-day treatment perioda
ADAMTS4 ADAMTS5 MMP3 MMP9 MMP13 COX2
EPA 0.1
μM
↓ ↓ ↓ x ↓ ↓
1 μM ↓ x ↓ x ↓ ↓
DHA 0.1
μM
x x x x x x
1 μM x x x x x x
aAll six catabolic/inflammatory genes were upregulated in the IL-1b-treated
explants relative to untreated controls. Arrows (↓) indicate a reduction in the
IL-1b-induced increase in gene expression associated with EPA or DHA
treatment. EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; MMPs,
matrix metalloproteinases; COX, cyclooxygenase; ADAMTS, a disintegrin and
metalloproteinase with a thrombospondin type 1 motif.
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